METHOD OF PROGNOSTICATION OF TUMOR SENSITIVITY TO NEOADJUVANT CHEMOTHERAPY FOR LUMINAL IN MOLECULAR-GENETIC TYPE OF BREAST CANCER

FIELD: medicine.SUBSTANCE: invention relates to medicine, namely, oncology, and may be used to prognosticate tumor sensitivity to neoadjuvant chemotherapy for luminal B molecular-genetic type of breast cancer. To do this, the tumor histotype and the degree of malignancy of the tumor are determined b...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Slonimskaya Elena Mikhajlovna, Zavyalova Marina Viktorovna, Cherdyntseva Nadezhda Viktorovna, Krakhmal Nadezhda Vasilevna, Litvyakov Nikolaj Vasilevich, Denisov Evgenij Vladimirovich, Perelmuter Vladimir Mikhajlovich, Gerashchenko Tatyana Sergeevna
Format: Patent
Sprache:eng ; rus
Schlagworte:
Online-Zugang:Volltext bestellen
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:FIELD: medicine.SUBSTANCE: invention relates to medicine, namely, oncology, and may be used to prognosticate tumor sensitivity to neoadjuvant chemotherapy for luminal B molecular-genetic type of breast cancer. To do this, the tumor histotype and the degree of malignancy of the tumor are determined by morphological examination of the neoplasm tissue at the light-optical level. Study is based on the classification of malignant neoplasms in the TNM system to determine the T index, conduct a morphological study of preparations of tumor tissue, determine the degree of expression of cellular polymorphism, determine the volume of tubular structures, calculate the number of mitoses and conduct a histological evaluation of the infiltrative component of the neoplasm tissue, where the number of different types of structures is counted: alveolar, tubular, trabecular, solid structures and discrete groups of tumor cells. Further, the value of the regression equation is calculated, the probability of tumor regression (P) is determined. For P≥50 % determine high, and at P